119434-75-2

Basic information

• Product Name: BOC-L-4-THIAZOLYLALANINE
• Synonyms: BOC-L-4-THIAZOLYLALANINE;BOC-3-(4-THIAZOLYL)-L-ALANINE;BOC-ALA(4-THIAZOLYL)-OH;BOC-ALA(4-THIAZOYL)-OH;BOC-ALA(4-THZ)-OH;BOC-S-THZALA-OH;(S)-N-BOC-4-THIAZOYLALANINE;(S)-N-ALPHA-T-BUTYLOXYCARBONYL-THIAZOL-4-YL-ALANINE
• CAS NO: 119434-75-2
• Molecular Formula: C₁₁H₁₆N₂O₄S
• Molecular Weight: 272.32
• Product Categories: Phenylalanine analogs and other aromatic alpha amino acids;Amino Acid Derivatives;a-amino
• Mol File: 119434-75-2.mol
• Article Data: 10

Chemical Properties

• Melting Point: 122℃
• Boiling Point: 456.788 °C at 760 mmHg
• Flash Point: 230.057 °C
• Appearance: White to pale yellow-beige/Powder
• Density: 1.288
• Vapor Pressure: 3.89E-09mmHg at 25°C
• Refractive Index: 1.5650 (estimate)
• Storage Temp.: Store at -15°C
• PKA: 3.53±0.10(Predicted)
• CAS DataBase Reference: BOC-L-4-THIAZOLYLALANINE(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-L-4-THIAZOLYLALANINE(119434-75-2)
• EPA Substance Registry System: BOC-L-4-THIAZOLYLALANINE(119434-75-2)

Safety Data

• Hazard Codes: Xi
• Safety Statements: 24/25
• WGK Germany: 3
• Hazardous Substances Data: 119434-75-2(Hazardous Substances Data)

Usage

Chemical Properties

White to pale yellowish-beige powder

InChI:InChI=1/C11H16N2O4S/c1-11(2,3)17-10(16)13-8(9(14)15)4-7-5-18-6-12-7/h5-6,8H,4H2,1-3H3,(H,13,16)(H,14,15)/p-1/t8-/m0/s1

Upstream product

• 115-08-2 thiocarboxamide 
• 151215-36-0 (S)-5-Bromo-2-tert-butoxycarbonylamino-4-oxo-pentanoic acid 
• 134038-91-8 1-<(S)-3-benzyloxycarbonyl-5-oxo-4-oxazolidinone>-3-diazo-2-propanone 
• 134038-93-0 4-<(S)-3-benzyloxycarbonyl-5-oxo-4-oxazolidinone>methylthiazole 
• 134038-92-9 1-<(S)-3-benzyloxycarbonyl-5-oxo-4-oxazolidinone>-3-chloro-2-propanone 
• 134038-95-2 ethyl (4-thiazolyl)methylacetamidoacetate 
• 131116-54-6 diethyl (4-thiazolyl)methylacetamidomalonate 
• 42294-32-6 diethyl 2-acetamido-2-(3-bromo-2-oxopropyl)malonate 
• 151215-34-8 N-tert-butoxycarbonyl-L-2-amino-4-bromo-4-pentenoic acid 
• 138742-45-7 ethyl 2-acetamido-4-bromopent-4-enoate 
• 151144-95-5 (S)-2-Acetylamino-4-bromo-pent-4-enoic acid 
• 151144-96-6 (S)-2-Amino-4-bromo-pent-4-enoic acid 
• 134038-94-1 diethyl 2-(2-bromoprop-2-en-1-yl)-2-acetamidopropanedioate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1285537-76-9 Boc-Thia-Leu-Phe-OMe 
• 1269406-90-7 1,1-dimethylethyl [(1S)-2-{[(3S)-1-(2-cyano-4-nitrophenyl)-3-pyrrolidinyl]amino}-2-oxo-1-(1,3-thiazol-4-ylmethyl)ethyl]carbamate 
• 125015-94-3 (2S,4S,5S)-5-[N-(t-butoxycarbonyl)-3-(4-thiazolyl)-L-alanyl]amino-6-cyclohexyl-4-hydroxy-2-(1-hydroxy-1-methylethyl)-N-butylhexanamide 
• 125015-89-6 (2S,4S,5S)-5-[N-(t-butoxycarbonyl)-3-(4-thiazolyl)-L-alanyl]amino-6-cyclohexyl-4-hydroxy-2-(1-hydroxy-1-methylethyl)-N-methylhexanamide 
• 132094-34-9 (3R,5S)-5-{(1S)-1-[N-(t-butoxycarbonyl)-3-(4-thiazolyl)-L-alanyl ]amino-2-cyclohexylethyl}-3-methyldihydrofuran-2(3H)-one 
• 116326-39-7 ES-6864 
• 119357-93-6 (3S,4S)-4-((S)-2-Amino-3-thiazol-4-yl-propionylamino)-5-cyclohexyl-3-hydroxy-pentanoic acid (2-morpholin-4-yl-ethyl)-amide 
• 1054660-24-0 {2-[(S)-1-{(S)-1-[(1S,2R)-1-Cyclohexylmethyl-2-((S)-3-ethyl-2-oxo-oxazolidin-5-yl)-2-hydroxy-ethylcarbamoyl]-2-thiazol-4-yl-ethylcarbamoyl}-2-(4-methoxy-phenyl)-ethylcarbamoyl]-1,1-dimethyl-ethyl}-carbamic acid tert-butyl ester 
• 122224-98-0 (R)-2-Benzyl-N-{(S)-1-[(1S,2R)-1-cyclohexylmethyl-2-((S)-3-ethyl-2-oxo-oxazolidin-5-yl)-2-hydroxy-ethylcarbamoyl]-2-thiazol-4-yl-ethyl}-4-morpholin-4-yl-4-oxo-butyramide 

Relevant articles and documents

Enantioselective synthesis of (S)-3-(4-thiazolyl)-2-tert- butoxycarbonylaminopropionic acid: A chiral building block for renin inhibitor

(S)-3-(4-Thiazolyl)-2-tert-butoxycarbonylaminopropionic acid (6), an important structural constituent of the renin inhibitor, has been synthesized from (Z)-3-(4-thiazolyl)-2-benzoylaminoprop-2-enoic acid (4b) by enantioselective hydrogenation using the Ru

Peptide derivatives having thiazolyl-alanine residue

A peptide derivation of the formula (I) or its pharmaceutically acceptable salt or hydrate thereof is disclosed. These compounds have superior ability over thyroid stimulating hormone (TRH) and its derivatives to activate the central nervous system, such as, for example, sustained acetylcholine releasing action, anti-reserpine action and locomotor increment.

ENCAPSULATED RENIN INHIBITOR COMPOSITION

A pharmaceutical composition comprising a solution of a tenin inhibitor of the formula: STR1 wherein R 1 is 4-piperazinyl, 1-methyl-4-piperazinyl, 1-methyl-1-oxo-4-piperazinyl, 2-oxo-4-piperazinyl, 4-morpholinyl, 4-thiomorpholinyl or 1-methyl-4-homopiperazinyl; R 2 is benzyl, p-methoxybenzyl, 2-phenylethyl, 1-naphthylmethyl or 2-naphthylmethyl;R 3 is 4-thiazolyl, 2-amino-4-thiazolyl, 2-thiazolyl, 5-thiazolyl, 1-pyrazolyl, 3-pyrazolyl, 1-imidazolyl, n-propyl, isopropyl, CH 3 S--or CH 3 SCH 2--;R 4 is loweralkyl or cyclopropyl;R 5 is hydrogen or loweralkyl; andX is CH 2 or NH; or a pharmaceutically acceptable salt, ester or prodrug thereof in a pharmaceutically acceptable solvent, said solution being encapsulated in a soft elastic gelatin capsule.